Fresenius Shares Slump After Novo Nordisk Kidney Disease Trial Shows Efficacy
By Mauro Orru
Shares of Germany's Fresenius and its dialysis-care business Fresenius Medical Care plunged Wednesday after Novo Nordisk said it would stop a trial to treat kidney failure in diabetes patients as it showed early signs of success, a development that could lower the number of dialysis patients.
At 0920 GMT, Fresenius Medical Care shares traded 19% lower at EUR32.10. Shares of Fresenius, which holds about 32% of Fresenius Medical Care, traded 12% lower at EUR24.43.
The Danish pharmaceutical giant said late Tuesday that it had decided to stop the trial early following a recommendation from an independent data monitoring committee due to early signs of efficacy. The trial started in 2019 to study the progression of kidney impairment and the risk of renal and cardiovascular mortality in people with type 2 diabetes and chronic kidney disease.
Novo Nordisk makes blockbuster weight-loss drugs Ozempic and Wegovy. Ozempic was originally developed to treat diabetes, but its use for weight loss has rapidly grown as both drugs share the same active ingredient, semaglutide, which works by mimicking a gut hormone called glucagon-like peptide-1, or GLP-1.
Citi analysts said that the early end of the trial would weigh on Fresenius and Fresenius Medical Care.
"We see kidney disease as one of the areas where GLP1s could potentially negatively impact the size of the relevant patient population over time," they wrote in a note to clients. "The early stopping of the FLOW trial indeed suggests such an impact."
Write to Mauro Orru at mauro.orru@wsj.com
(END) Dow Jones Newswires
October 11, 2023 05:38 ET (09:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations